Sophiris Bio (SPHS) Trading 13.4% Higher
Sophiris Bio Inc (NASDAQ:SPHS) shares traded up 13.4% on Thursday . The company traded as high as $1.20 and last traded at $1.10. 532,623 shares were traded during mid-day trading, an increase of 273% from the average session volume of 142,676 shares. The stock had previously closed at $0.97.
A number of research analysts have recently weighed in on the company. ValuEngine upgraded Sophiris Bio from a “hold” rating to a “buy” rating in a research report on Thursday, December 13th. Maxim Group set a $6.00 price target on Sophiris Bio and gave the company a “buy” rating in a research report on Thursday, December 6th. HC Wainwright set a $10.00 price target on Sophiris Bio and gave the company a “buy” rating in a research report on Wednesday, November 14th. Finally, Piper Jaffray Companies dropped their price target on Sophiris Bio to $5.00 and set an “overweight” rating for the company in a research report on Wednesday.
The stock has a market cap of $28.85 million, a price-to-earnings ratio of -2.75 and a beta of 2.94.
ILLEGAL ACTIVITY NOTICE: This report was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://theolympiareport.com/2019/03/14/sophiris-bio-sphs-trading-13-4-higher.html.
Sophiris Bio Company Profile (NASDAQ:SPHS)
Sophiris Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer.
Featured Article: Guidelines for Successful Channel Trading
Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.